Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.

ABSTRACT: Although the molecular landscape of squamous cell carcinoma of the head and neck (SCCHN) has been largely deciphered, only one targeted therapy has been approved to date without any molecular selection, namely cetuximab. Cetuximab is a monoclonal antibody targeting EGFR. It has been shown to improve overall survival in the locally advanced setting in combination with radiotherapy and the recurrent and/or metastatic setting in combination with a platinum compound and 5FU. Beside EGFR targeting agents, antiangiogenic agents have been shown to produce antitumor activity but were associated with substantial toxicity. Buparlisib that targets PI3K was also shown to improve survival in combination with paclitaxel in an unselected patient population. Several other targeted therapies have been deve

SUBMITTER: Saada-Bouzid E 

PROVIDER: S-EPMC6381014 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature